GLPG
HEALTHCAREGalapagos NV
$28.81+0.42 (+1.48%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving GLPG Today?
No stock-specific AI insight has been generated for GLPG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$24.74$37.78
$28.81
Fundamentals
Market Cap$1.9B
P/E Ratio5.1
EPS$5.68
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.3%
Debt / Equity—
Trading
Volume92K
Avg Volume (10D)—
Shares Outstanding65.9M
GLPG News
21 articles- Galapagos Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Galapagos Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026Yahoo Finance·Apr 28, 2026
- RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1Yahoo Finance·Apr 24, 2026
- Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines AssetsYahoo Finance·Apr 4, 2026
- Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational TrialsMarketbeat·Mar 31, 2026
- Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos CollaborationYahoo Finance·Mar 31, 2026
- Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune DiseasesBenzinga·Mar 31, 2026
- Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation PipelineYahoo Finance·Mar 27, 2026
- Galapagos Announces Nomination of Gino Santini to its Board of DirectorsYahoo Finance·Mar 26, 2026
- Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ MeetingsYahoo Finance·Mar 26, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Mar 24, 2026
- Gilead Strengthens Inflammation Portfolio With Ouro Medicines DealYahoo Finance·Mar 24, 2026
- Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains.Yahoo Finance·Mar 24, 2026
- Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion AcquisitionBenzinga·Mar 24, 2026
- Gilead Sciences to Acquire Ouro Medicines in Up to $2.18 Billion DealYahoo Finance·Mar 24, 2026
- Gilead to buy Ouro Medicines for up to $2.2 billionYahoo Finance·Mar 23, 2026
- Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune DiseasesYahoo Finance·Mar 23, 2026
- Galapagos Receives Transparency Notification from Bank of AmericaYahoo Finance·Mar 17, 2026
- CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsightYahoo Finance·Mar 10, 2026
- Galapagos Receives Transparency Notifications from Bank of AmericaYahoo Finance·Mar 10, 2026
All 21 articles loaded
Price Data
Open$27.83
Previous Close$28.39
Day High$28.27
Day Low$27.58
52 Week High$37.78
52 Week Low$24.74
52-Week Range
$24.74$37.78
$28.81
Fundamentals
Market Cap$1.9B
P/E Ratio5.1
EPS$5.68
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.3%
Debt / Equity—
Trading
Volume92K
Avg Volume (10D)—
Shares Outstanding65.9M
About Galapagos NV
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—